DRUG DESIGNATION: Pfizer says U.S. regulators have classified its experimental pill for advanced, often-deadly breast cancer as a breakthrough therapy. That’s done to speed up development and review of treatments seen as big advances.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.